Neuroendocrine Tumors - Pipeline Insight, 2025

This “Neuroendocrine Tumors - Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Neuroendocrine Tumors: Understanding

Neuroendocrine Tumors: Overview

A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have a specific effect on the activity of other organs or cells in the body. Most NETs take years to develop and grow slowly.

Neuroendocrine tumors may be functional or nonfunctional, depending on their hormone secretion. Functional NETs produce excess hormones, while nonfunctional tumors don’t produce hormones or enough of them to cause noticeable symptoms. Which hormone or hormones the cancer cells secrete depends on where the cancer develops. About 60 percent of NETs are categorized as nonfunctional, according to the American Society of Clinical Oncology (ASCO). The symptoms of the NET and the treatment plan will likely depend on whether the tumor is functional or nonfunctional.

Neuroendocrine tumors (NETs) can be discovered for many different reasons because there is no single set of common symptoms. Symptoms are changes that one can feel in their body. In its early stages, a NET often causes no symptoms and may only be detected during an unrelated x-ray or surgery for another condition. If a person with a NET has symptoms, those symptoms may be associated with the size and/or location of the tumor or with the release of hormones, such as carcinoid syndrome.

The diagnosis of a NET requires a coordinated multidisciplinary effort involving medical oncologists, surgeons, interventional radiologists and pathologists. Results from pathology testing, hormonal testing, and diagnostic and functional imaging are integrated to form a comprehensive diagnostic picture. Surgery is the removal of the tumor and some surrounding healthy tissue during an operation. A surgical oncologist is a doctor who specializes in cancer surgery. Completely removing the entire tumor is the standard treatment, when possible. Most localized NETs are successfully treated with surgery alone. The surgeon will usually remove some tissue surrounding the tumor, called a margin, in an effort to leave no traces of cancer in the body. 

"Neuroendocrine Tumors - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuroendocrine Tumors pipeline landscape is provided which includes the disease overview and Neuroendocrine Tumors treatment guidelines. The assessment part of the report embraces, in depth Neuroendocrine Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuroendocrine Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Neuroendocrine Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Neuroendocrine Tumors.

Neuroendocrine Tumors Emerging Drugs Chapters

This segment of the Neuroendocrine Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neuroendocrine Tumors Emerging Drugs

CAM2029: Camurus

CAM2029 is a long-acting subcutaneous depot of octreotide under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. Currently, the drug is in the Phase III stage of its development for the treatment of gastroentero pancreatic neuroendocrine tumors.

AlphaMedix: Orano Med

AlphaMedix is a somatostatin receptor targeting peptide radiolabeled with 212Pb. Somatostatin receptors are overexpressed in most neuroendocrine tumors, a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as ovaries, heart, and prostate. After the promising results of the Phase I clinical trial launched early 2018, a Phase II was initiated late 2021 to assess the efficacy of Alphamedix in the treatment of neuroendocrine tumors. The study is currently recruiting patients in the US. Currently the drug is in Phase II stage of its clinical development.

Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of its development.

Neuroendocrine Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Neuroendocrine Tumors drugs segregated based on following parameters that define the scope of the report.

Major Players in Neuroendocrine Tumors
There are approx. 70+ key companies which are developing the therapies for Neuroendocrine Tumors. The companies which have their Neuroendocrine Tumors drug candidates in the most advanced stage, i.e. Phase III include, Camurus.

Phases
The report covers around 75+ products under different phases of clinical development, like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types, such as:

• Monoclonal antibody
• Small molecule
• Peptide

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neuroendocrine Tumors: Pipeline Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuroendocrine Tumors therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuroendocrine Tumors drugs.

Neuroendocrine Tumors Report Insights

• Neuroendocrine Tumors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Neuroendocrine Tumors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Neuroendocrine Tumors drugs?
• How many Neuroendocrine Tumors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuroendocrine Tumors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neuroendocrine Tumors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neuroendocrine Tumors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Camurus
• Vyriad, Inc.
• TYK Medicines
• Orano Med
• Advanced Accelerator Applications
• Sinotau Pharmaceutical Group
• ITM Solucin GmbH
• Molecular Targeting Technologies, Inc.
• Biotheus Inc.
• Aadi Bioscience, Inc.
• TaiRx, Inc.

Key Products

• CAM2029
• Voyager-V1
• TY-1091
• AlphaMedix
• ASTX727
• Lutetium[177Lu] Oxodotreotide
• 177Lu-Edotreotide
• 177Lu-DOTA-EB-TATE
• PM8002
• Nab-sirolimus
• CVM-1118

This product will be delivered within 2-4 business days.